DBV Technologies Invited to Present at future Conferences Investors

DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT) today announced that members of its management have been invited to present, as well as to keep appointments investors at upcoming conferences investors :

Download the free guide
Boost your gains

Charles Ruban, Chief Commercial officer, and Susanna Mesa, Senior Vice-President, Strategy, will present at the conference Jefferies 2017 Global Healthcare Conference in New York, NY, on Wednesday, June 7, 2017 at 2: 30 am (local time).
Susanna Mesa, SVP, Strategy, will present at the 38th annual edition of the conference Goldman Sachs Healthcare Conference in Rancho Palos Verdes, California (Usa), Tuesday, 13 June 2017 at 11.20 (local time).
A webcast of the conference Jefferies 2017 Global Healthcare will be available on the website of DBV Technologies, in the Investor Relations section : http://www.dbv-technologies.com/fr/relations-investisseurs. A webcast of the presentation will also be available on the website of DBV Technologies, in the hour of the event.

About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with vast fields of potential applications in immunotherapy. Viaskin uses immunotherapy by means epicutaneous, or AVAILABLE on a®, the method developed by DBV for administering biologically active compounds to the immune system through intact skin. With this new category of product candidates non-invasive and self‑administered, the company strives to transform the care of patients with a food allergy, for which there is no approved treatment. The programs of the DBV related to food allergies include clinical trials of Viaskin Peanut and Viaskin Milk, as well as the clinical development of Viaskin Egg. DBV is also in the process of conducting a clinical study proof-of-concept in Humans for the treatment of esophagitis eosinophilic and continues to explore the potential applications of its platform in the field of vaccination and other immune diseases.
DBV Technologies has a global headquarters in Montrouge, France and New York, in the United States. The company’s shares are traded on segment A of Euronext Paris (ticker : DBV, ISIN code : FR0010417345), are part of the index SBF 120 and are also traded on the Nasdaq Global Select Market under the form of American Depositary Shares (each representing half of one ordinary share) (ticker : DBVT). For more information on DBV Technologies, please visit our website : www.dbv-technologies.com.

Download the free guide
Boost your gains

Like this post? Please share to your friends:
Leave a Reply